Andrew K. Balo Sells 5,597 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) insider Andrew K. Balo sold 5,597 shares of the company’s stock in a transaction dated Thursday, September 9th. The stock was sold at an average price of $546.78, for a total transaction of $3,060,327.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of DexCom stock opened at $542.23 on Wednesday. The company has a current ratio of 5.78, a quick ratio of 5.25 and a debt-to-equity ratio of 0.86. DexCom, Inc. has a 12-month low of $305.63 and a 12-month high of $559.75. The firm has a market capitalization of $52.46 billion, a price-to-earnings ratio of 103.28, a PEG ratio of 14.59 and a beta of 0.77. The firm’s 50 day simple moving average is $497.06 and its two-hundred day simple moving average is $421.02.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 29th. The medical device company reported $0.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.33. DexCom had a net margin of 24.45% and a return on equity of 16.17%. The business had revenue of $595.10 million for the quarter, compared to analyst estimates of $548.02 million. On average, sell-side analysts predict that DexCom, Inc. will post 2.46 EPS for the current fiscal year.

Several brokerages have recently weighed in on DXCM. Barclays began coverage on shares of DexCom in a research report on Monday, May 24th. They issued an “overweight” rating and a $500.00 price target for the company. Canaccord Genuity upped their price target on shares of DexCom from $455.00 to $500.00 and gave the stock a “buy” rating in a research report on Friday, July 30th. Stephens upped their price target on shares of DexCom from $468.00 to $546.00 and gave the stock an “overweight” rating in a research report on Friday, July 30th. Oppenheimer upped their price target on shares of DexCom from $500.00 to $525.00 and gave the stock an “outperform” rating in a research report on Friday, July 30th. Finally, Morgan Stanley upped their price target on shares of DexCom from $410.00 to $510.00 and gave the stock an “equal weight” rating in a research report on Monday, August 2nd. Two investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, DexCom currently has an average rating of “Buy” and a consensus price target of $500.00.

Institutional investors have recently modified their holdings of the business. Arkadios Wealth Advisors increased its stake in DexCom by 58.5% during the 2nd quarter. Arkadios Wealth Advisors now owns 65 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 24 shares in the last quarter. Parkside Financial Bank & Trust grew its position in DexCom by 140.7% during the second quarter. Parkside Financial Bank & Trust now owns 65 shares of the medical device company’s stock valued at $28,000 after buying an additional 38 shares during the period. CX Institutional grew its position in DexCom by 155.6% during the second quarter. CX Institutional now owns 69 shares of the medical device company’s stock valued at $29,000 after buying an additional 42 shares during the period. Ameritas Investment Company LLC acquired a new stake in DexCom during the first quarter valued at $27,000. Finally, Glassman Wealth Services grew its position in DexCom by 141.2% during the first quarter. Glassman Wealth Services now owns 82 shares of the medical device company’s stock valued at $29,000 after buying an additional 48 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

About DexCom

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.

See Also: CBOE Russell 2000® Volatility Index

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.